- Email: [email protected]
4888281 Method of catalyzing chemical reactions
PATENT ABSTRACTS 4886782 MALARIAL
IMMUNOGEN
Michael A Good, Ja Berzofsky, Louis H Miller assigned to The United States of America as represented by the Department of Health and Human Services The circumsporozoite (CS) protein of Plasmodium falciparum has been analyzed to develop a new anti-sporozoite malarial vaccine, Localization of sites for T-cell recognition on this molecule is critical for vaccine design. By using an algorithm designed to predict T-cell sites and a large panel of H-2 congenic mice, a major nonrepetitive T-cell was located. When a synthetic peptide corresponding to this site was covalently linked to the major B-cell site on the molecule, an immunogen capable of eliciting a high titer antibody response was formed. This peptide sequence is capable of priming helper Tcells for a secondary response to the intact CS protein. This site represents the first helper T-cell site described for the CS molecule outside of the repetitive region, and is a major immunodominant T-site on the molecule. The approach described herein is useful in the rational design and construction of more efficacious vaccines.
4888163 DIAGNOSTIC AGENT FOR BREAST CANCER OR TUMOR Akiko Kubodera, Touichi Tanaka, Yukimichi Komori, Chiba, Japan assigned to Nihon MediPhysics Co Ltd A radioactive diagnostic agent for imaging a breast cancer or tumor, which comprises an antiestriol-3-sulfate antibody labeled with a radioisotope as an essential component,
4888169 BORDETELLA
445
4888170 VACCINES OBTAINED FROM ANTIGENIC GENE PRODUCTS OF RECOMBINANT GENES Roy Curtiss assigned to Research Corporation This invention relates to a vaccine for the iramunization of a vertebrate, comprising: an avirulent derivative o f a pathogenic microbe that expresses a recombinant gene derived from a pathogen of said vertebrate it being provided that said avirulent microbe does not normally exchange genetic material with said pathogen, to produce an antigen capable of inducing an iramune response in said vertebrate against said pathogen.
4888279 NOVEL IMMUNOSORBENT ASSAYS EMPLOYING ANTIBIOTIC KEYING AGENTS Allen R Zeiger assigned to Thomas Jefferson University New immunosorbent enzyme assays are provided employing antibiotic keying agents for binding a molecular species to be detected to a test surface followed by binding of an antibody specific for the species and detection of the antibody-species binding. In accordance with preferred embodiments, soluble peptidoglycan is assayed in a fluid binding it to a test surface with vancomycin, reacting the bound material with a peptidoglycan specific antibody, and measuring the extent of the antibody reaction. Assessment of bodily fluids and fermenation broths for the presence of certain kinds of antibiotics is one object of this invention. Assessment of sera for the presence of antibodies that have specificity for soluble peptidoglycans is another object of this invention. Assessment of bodily states in maremals is another object of the invention.
BRONCHISEPTICA
VACCINE Albert Brown, Joseph C Frantz, Richard H Peetz assigned to Norden Laboratories Inc A vaccine for protecting canines against infection by Bordetella bronchiseptica is prepared by inactivating whole cells with glutaraldehyde,
4888281 METHOD OF CATALYZING CHEMICAL REACTIONS Geral Schochetman, Richard J Massey assigned to Igen Inc
446
PATENT ABSTRACTS
A method for increasing the rate of chemical reactions involving the conversion of at least one reactant to at least one product involves contacting the reactant with an appropriate monoclonal antibody under conditions permitting the formation of a complex between the antibody and the reactant. The complexed reactant is converted to the product which is then released from the complex. The monoclonal antibody may employ a cofactor and may be directed to a known substrate of an enzyme. Methods for preparing such monoclonal antibodies are also disclosed,
4888284 DIPEPTIDASE, ITS ISOLATION F R O M L A C T I C ACID B A C T E R I A , ANTIBODIES AGAINST THE DIPEPTIDASE, THE USE OF THE DIPEPTIDASE AND OF THE ANTIBODIES AGAINST IT Willem N Konings, Aart van Boven, Haren, Netherlands assigned to Rijksuniversiteit te Groningen This invention relates to dipeptidase of lactic acid bacteria in isolated form, characterized by a molecular weight of 55 kD +/-5 kD; an isoelectric point of 4.4 +/-0.4; a substrate range including the dipeptides leu-leu, leu-met, leu-val, leu-gly, vaMeu, phe-leu and ala-ala, but not the dipeptides his-leu, gamma-glu-leu, gly-leu, alpha-glu-ala and peptides of 3 or more amino acid residues; and a hydrolyzing activity with a temperature optimum at 50 degrees C.+/-10 degrees C., a pH optimum at 8+/-1, and sensitivity to the metal chelating EDTA and to the reducing agents dithiotreitol and mercaptoethanol. The invention also relates to a process for isolating the dipeptidase from lactic acid bacteria; to the use of the dipeptidsae for preparing polyclonal or monoclonal antibodies having an affinity to, and/or specificity for, the dipeptidase; to polyclonal and monoclonal antibodies having an affinity to, and/or specificity for, the dipeptidase; to the use of polyclonal or monoclonal antibodies for detecting the dipeptidase in, or removing or isolating it from, a mixture containing the dipeptidase; to the use of the dipeptidase in the production of food products, and to food products produced using the dipeptidase.
4888287 RAPID DIFFERENTIATION OF FUNGI FROM BACTERIA USING POLYENE ANTIBIOTICS Peggy W Cichanowicz, Robert T Belly assigned to Eastman Kodak Company Rapid differentiation between viable fungi (for example, yeast) and viable bacteria is accomplished with certain polyene antibiotics which are used in combination with a compound which is normally reducible by both the fungi and the bacteria. The antibiotics selectively and substantially inhibit the reduction of the reducible compound by the fungi but do not affect the reducing capacity of the bacteria. The particular antibiotics useful are polyenes which selectively affect the function of the cytoplasmic membrane of fungi.
4888290 MONOCLONAL ANTIBODY SPECIFIC TO HIV ANTIGENS Kenneth H Kortright, David E Hofheinz, Carol Sullivan, Gary Toedter assigned to Coulter Corporation A hybrid cell line is provided which is capable of producing monoclonal antibodies which bind to HIV core antigen P55, the precursor protein coded for the gag gene, the core protein P24 and partial breakdown products P39 and P33. The monoclonal antibody embodying the invention does not bind the PI8 core protein or any HIV envelope antigens. The cellline of the invention was developed by a unique immunization protocol in which BALB/c mice were immunized over a series of multiple infusions using a select group of immunogens and a conventional myeloma cell line for fusion with the murine splenocytes harvested. The monoclonal antibody is identified as the KC-57 antibody. This monoclonal antibody is especially useful for a solid phase immunoassay in which the monoclonal antibody is detected in its binding to HIV antigens found in a serum or plasma sample from a human patient. The cell line which produces the KC-57 monoclonal antibody has been deposited in the American Type Culture Collection, Rockville, Md. and assigned A.T.C.C. No. HB 9585.
IMMUNOGEN
Michael A Good, Ja Berzofsky, Louis H Miller assigned to The United States of America as represented by the Department of Health and Human Services The circumsporozoite (CS) protein of Plasmodium falciparum has been analyzed to develop a new anti-sporozoite malarial vaccine, Localization of sites for T-cell recognition on this molecule is critical for vaccine design. By using an algorithm designed to predict T-cell sites and a large panel of H-2 congenic mice, a major nonrepetitive T-cell was located. When a synthetic peptide corresponding to this site was covalently linked to the major B-cell site on the molecule, an immunogen capable of eliciting a high titer antibody response was formed. This peptide sequence is capable of priming helper Tcells for a secondary response to the intact CS protein. This site represents the first helper T-cell site described for the CS molecule outside of the repetitive region, and is a major immunodominant T-site on the molecule. The approach described herein is useful in the rational design and construction of more efficacious vaccines.
4888163 DIAGNOSTIC AGENT FOR BREAST CANCER OR TUMOR Akiko Kubodera, Touichi Tanaka, Yukimichi Komori, Chiba, Japan assigned to Nihon MediPhysics Co Ltd A radioactive diagnostic agent for imaging a breast cancer or tumor, which comprises an antiestriol-3-sulfate antibody labeled with a radioisotope as an essential component,
4888169 BORDETELLA
445
4888170 VACCINES OBTAINED FROM ANTIGENIC GENE PRODUCTS OF RECOMBINANT GENES Roy Curtiss assigned to Research Corporation This invention relates to a vaccine for the iramunization of a vertebrate, comprising: an avirulent derivative o f a pathogenic microbe that expresses a recombinant gene derived from a pathogen of said vertebrate it being provided that said avirulent microbe does not normally exchange genetic material with said pathogen, to produce an antigen capable of inducing an iramune response in said vertebrate against said pathogen.
4888279 NOVEL IMMUNOSORBENT ASSAYS EMPLOYING ANTIBIOTIC KEYING AGENTS Allen R Zeiger assigned to Thomas Jefferson University New immunosorbent enzyme assays are provided employing antibiotic keying agents for binding a molecular species to be detected to a test surface followed by binding of an antibody specific for the species and detection of the antibody-species binding. In accordance with preferred embodiments, soluble peptidoglycan is assayed in a fluid binding it to a test surface with vancomycin, reacting the bound material with a peptidoglycan specific antibody, and measuring the extent of the antibody reaction. Assessment of bodily fluids and fermenation broths for the presence of certain kinds of antibiotics is one object of this invention. Assessment of sera for the presence of antibodies that have specificity for soluble peptidoglycans is another object of this invention. Assessment of bodily states in maremals is another object of the invention.
BRONCHISEPTICA
VACCINE Albert Brown, Joseph C Frantz, Richard H Peetz assigned to Norden Laboratories Inc A vaccine for protecting canines against infection by Bordetella bronchiseptica is prepared by inactivating whole cells with glutaraldehyde,
4888281 METHOD OF CATALYZING CHEMICAL REACTIONS Geral Schochetman, Richard J Massey assigned to Igen Inc
446
PATENT ABSTRACTS
A method for increasing the rate of chemical reactions involving the conversion of at least one reactant to at least one product involves contacting the reactant with an appropriate monoclonal antibody under conditions permitting the formation of a complex between the antibody and the reactant. The complexed reactant is converted to the product which is then released from the complex. The monoclonal antibody may employ a cofactor and may be directed to a known substrate of an enzyme. Methods for preparing such monoclonal antibodies are also disclosed,
4888284 DIPEPTIDASE, ITS ISOLATION F R O M L A C T I C ACID B A C T E R I A , ANTIBODIES AGAINST THE DIPEPTIDASE, THE USE OF THE DIPEPTIDASE AND OF THE ANTIBODIES AGAINST IT Willem N Konings, Aart van Boven, Haren, Netherlands assigned to Rijksuniversiteit te Groningen This invention relates to dipeptidase of lactic acid bacteria in isolated form, characterized by a molecular weight of 55 kD +/-5 kD; an isoelectric point of 4.4 +/-0.4; a substrate range including the dipeptides leu-leu, leu-met, leu-val, leu-gly, vaMeu, phe-leu and ala-ala, but not the dipeptides his-leu, gamma-glu-leu, gly-leu, alpha-glu-ala and peptides of 3 or more amino acid residues; and a hydrolyzing activity with a temperature optimum at 50 degrees C.+/-10 degrees C., a pH optimum at 8+/-1, and sensitivity to the metal chelating EDTA and to the reducing agents dithiotreitol and mercaptoethanol. The invention also relates to a process for isolating the dipeptidase from lactic acid bacteria; to the use of the dipeptidsae for preparing polyclonal or monoclonal antibodies having an affinity to, and/or specificity for, the dipeptidase; to polyclonal and monoclonal antibodies having an affinity to, and/or specificity for, the dipeptidase; to the use of polyclonal or monoclonal antibodies for detecting the dipeptidase in, or removing or isolating it from, a mixture containing the dipeptidase; to the use of the dipeptidase in the production of food products, and to food products produced using the dipeptidase.
4888287 RAPID DIFFERENTIATION OF FUNGI FROM BACTERIA USING POLYENE ANTIBIOTICS Peggy W Cichanowicz, Robert T Belly assigned to Eastman Kodak Company Rapid differentiation between viable fungi (for example, yeast) and viable bacteria is accomplished with certain polyene antibiotics which are used in combination with a compound which is normally reducible by both the fungi and the bacteria. The antibiotics selectively and substantially inhibit the reduction of the reducible compound by the fungi but do not affect the reducing capacity of the bacteria. The particular antibiotics useful are polyenes which selectively affect the function of the cytoplasmic membrane of fungi.
4888290 MONOCLONAL ANTIBODY SPECIFIC TO HIV ANTIGENS Kenneth H Kortright, David E Hofheinz, Carol Sullivan, Gary Toedter assigned to Coulter Corporation A hybrid cell line is provided which is capable of producing monoclonal antibodies which bind to HIV core antigen P55, the precursor protein coded for the gag gene, the core protein P24 and partial breakdown products P39 and P33. The monoclonal antibody embodying the invention does not bind the PI8 core protein or any HIV envelope antigens. The cellline of the invention was developed by a unique immunization protocol in which BALB/c mice were immunized over a series of multiple infusions using a select group of immunogens and a conventional myeloma cell line for fusion with the murine splenocytes harvested. The monoclonal antibody is identified as the KC-57 antibody. This monoclonal antibody is especially useful for a solid phase immunoassay in which the monoclonal antibody is detected in its binding to HIV antigens found in a serum or plasma sample from a human patient. The cell line which produces the KC-57 monoclonal antibody has been deposited in the American Type Culture Collection, Rockville, Md. and assigned A.T.C.C. No. HB 9585.